Abiopharma

🔍 Plenge Robert M (Executive)

Company: BRISTOL MYERS SQUIBB CO (BMY)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 1,107 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,946.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 124 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 16,822.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 436 shares of Common Stock, $0.10 par value at $60.13 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 16,386.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 2,342 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,728.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 253 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 18,475.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 927 shares of Common Stock, $0.10 par value at $60.13 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 17,548.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 14,052 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,600.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 6,900 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 24,700.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 3,172 shares of Common Stock, $0.10 par value at $60.13 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 21,528.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: H | nature_of_ownership: BMS Savings and Investment Program | shares_owned_after: 3,026.38 | Footnotes: F7
• Holds 0 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: H | nature_of_ownership: Family Trust | shares_owned_after: 200.00 | Footnotes: F8
• Sold 1,107 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2026-03-10 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F9, F1
• Sold 2,342 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2027-03-10 | equity_swap_involved: 0 | shares_owned_after: 2,342.00 | transaction_form_type: 4 | Footnotes: F9, F4
• Sold 14,052 shares of Performance Shares (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2026-03-10 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F10, F5
• Acquired 17,959 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2029-03-10 | equity_swap_involved: 0 | shares_owned_after: 17,959.00 | transaction_form_type: 4 | Footnotes: F11, F12
• Acquired 26,939 shares of Performance Shares (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2029-03-10 | equity_swap_involved: 0 | shares_owned_after: 26,939.00 | transaction_form_type: 4 | Footnotes: F13, F13

Footnotes:

• F1: Represents vesting of one-quarter market share units granted on March 10, 2022.
• F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
• F3: Shares withheld for payment of taxes upon vesting of awards.
• F4: Represents vesting of one-quarter market share units granted on March 10, 2023.
• F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
• F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board.
• F7: Based on recent 401(k) plan statement.
• F8: Shares held in a family trust, where reporting person is a beneficiary.
• F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
• F10: Each performance share unit converted into one share of common stock upon distribution in the first quarter of 2026.
• F11: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
• F12: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
• F13: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
• REMARKS: Exhibit 24 - Power of Attorney